The role of ribosomal protein S6 kinase 1(S6K1) on cisplatin resistance in chronic myeloid leukemia (CML)
博士 === 國立成功大學 === 基礎醫學研究所 === 105 === More than 95% chronic myeloid leukemia (CML) patients carry the constitutively activated tyrosine kinase, BCR-ABL fusion protein. Therefore, tyrosine kinase inhibitors (TKIs) are designed for CML treatment. However, some patients have no response to TKIs especia...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2017
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/pdph3y |